InDex to Present Positive Results of Kappaproct for Ulcerative Colitis at Digestive Disease Week Meeting

InDex to Present Positive Results of Kappaproct for Ulcerative Colitis at Digestive Disease Week Meeting
InDex Pharmaceuticals today presents positive results of its lead drug candidate Kappaproct (cobitolimod) to treat moderate to severe active ulcerative colitis (UC) during the Digestive Disease Week congress now underway in Chicago. The Swedish company said in a press release that it is presenting two posters showing that the drug induces remission of UC symptoms. Kappaproct (cobitolimod) binds to the toll-like receptor 9 (TLR9), which enhances its function and leads to production
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *